
Costly outpatient services in corporate hospitals leave patients high and dry
This explains why they charge hefty sums ranging from Rs 1,000 to Rs 2,500 per visit. For other patients too, the same amount is charged by these in-house doctors, be they surgeons or physicians.
Such squeezing takes place in corporate hospitals across the city and elsewhere due to the state medical authorities' laxity in regulating this aberration. Due to the lack of regulatory oversight, managements of corporate hospitals are raking in the moolah unethically as if they are not accountable to anybody.
There was a time when outpatient services were economical than hospitalization, but now, due to now the rising charges, outpatient expenses are becoming a cause for concern for the common people. The hospitals are charging at least Rs 1,000 for normal OP services and amounts ranging from Rs 1,500 to Rs 3,000 for specialized consultations like cardiology, neurology, nephrology etc., depending on the size and 'brand value'of the hospital.
Insurance cover is normally for in-patient services. However, the charges for outpatient services are draining their financial resources. Aside from high registration charges, patients are forced to pay indiscriminate and excessive charges for a battery of diagnostic tests prescribed by doctors. The woes of the patients do not end at registration and consultations but continue while they move out of the hospitals in the form of prescription of medicines. That apart, the doctors in such hospitals prescribe medicines that are only available in their in-house pharmacies, which are costly compared to the prices in outside medical shops.
It may be mentioned here that the National Medical Commission (NMC) has issued guidelines asking doctors to prescribe drugs using generic names, avoid unnecessary medications and avoid irrational fixed dose combinations. The State Medical Councils have the authority to take disciplinary action against doctors who violate these regulations.
The Supreme Court, while hearing a PIL plea, had suggested the states to introduce a policy so that hospitals do not compel patients to buy essential medical items from in-house pharmacies at inflated rates. Judge Justice Surya Kant highlighted concerns over patients being left with no choice but to purchase medicines, implants and medical devices at exorbitant prices from hospital-linked pharmacies. The Court noted that regulations in private healthcare remain inconsistent, leading to potential exploitation. The petitioner had argued that the practice leads to blackmailing, depriving patients of their rights to have fair pricing.
K Shashikala (name changed), who wanted to see a senior endocrinologist for thyroid was asked to pay Rs 900 (Including 100 for registration) for walk-in consultation or Rs 1,000 for registration through phone. During their next visit to show their diagnostic report, they were asked to come to a corporate hospital if it was very urgent as the doctor provides the services there.
The patient postponed the visit for two-three days to avoid paying the registration fee in the corporate hospital.
When asked, a senior official from the Health Department, who did not want to be identified said that while the doctors have the right to prescribe the combinations as per the needs of the patients, the patients cannot be forced to take medicines from the in-house pharmacies. The official further said that the pricing of the outpatient consultations also depended on the facilities the hospital provided and the modern equipment they possessed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
25 minutes ago
- Business Standard
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.


Time of India
3 hours ago
- Time of India
897 deaths from mosquito, water-borne diseases in AMC hospitals since 2015
1 2 SLUG: RTI Data Ahmedabad: For the first time, detailed figures on deaths caused by water-borne and mosquito-borne diseases in city have come to light through a Right to Information (RTI) application. The data reveals that over the past decade, 897 patients lost their lives to such illnesses in five hospitals managed by the Ahmedabad Municipal Corporation (AMC). Among these, 302 deaths occurred during treatment for dengue — the highest number recorded for any single disease in this category over the ten-year period. These figures mark the first comprehensive disclosure of mortality linked to these diseases in AMC-run hospitals. The executive president of the City Congress Committee's minority department, advocate Atik Saiyed, stated, "From 2015 to 2025 (up to May 22, 2025), we requested statistical data on how many citizens received treatment and how many died during treatment for diarrhoea, typhoid, jaundice, cholera, malaria, and dengue in AMC-run Shardaben Hospital, Infectious Disease Hospital, LG Hospital, VS Hospital, and SVP Hospital. The information provided by these hospitals showed a total of 71,886 diarrhoea cases, with 182 deaths. There were 14,918 typhoid cases, resulting in 23 deaths. There were 18,292 cases of jaundice, with 253 deaths. Cholera accounted for 2,202 cases, with eight deaths. Malaria had 13,851 cases, with 129 deaths. Dengue recorded 22,010 cases, with 302 deaths. In total, 897 patients died during treatment in these five hospitals over the last ten years." You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad He further stated, "Ensuring access to clean water and food for citizens is the responsibility of AMC, but the system failed. Despite an annual budget of Rs 14,000 crore, citizens are succumbing to diseases like cholera, jaundice, dengue, and diarrhoea. Tax-paying citizens are not receiving clean water and food. Broken roads and polluted air are also realities in the city. We demand that the Ahmedabad municipal commissioner and mayor provide compensation to citizens who died from water- and mosquito-borne diseases due to AMC's negligence. " Notably, an example is necessary to understand how AMC's health department conceals epidemic data, he added. Information provided in the RTI revealed that SVP Hospital reported 10 deaths from jaundice and nine from diarrhoea between Jan and May 2025. However, the health department's statistics released on July 5, 2025, for the period from Jan to July 2025, did not report any deaths from diarrhoea or jaundice.


Time of India
4 hours ago
- Time of India
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 이 게임은 대부분의 TV 프로그램보다 더 재미있어요 – 게다가 무료예요. Raid: Shadow Legends 플레이하기 Undo The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. Live Events India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores.